Genmab's van Berkel joins ADC Therapeutics
This article was originally published in Scrip
ADC Therapeutics, a drug development company targeting cancer with antibody-drug conjugate therapies, has appointed former Genmab vice-president Dr Patrick van Berkel senior vice-president of R&D. Dr van Berkel served at Genmab for over nine years in different division, most recently as VP of chemistry, manufacturing and control, research & development since 2008.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.